National Guideline Clearinghouse | Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases.

National Guideline Clearinghouse | Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases.

National Institute for Health and Care Excellence (NICE)

• Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases.

Guideline Title Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. Bibliographic Source(s) National Institute for Health and Care Excellence (NICE). Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Jan 27. 65 p. (Technology appraisal guidance; no. 376).  Guideline Status This is the current release of the guideline. This guideline meets NGC's 2013 (revised) inclusion criteria.